Prevalence and Management of Treatment-Resistant Depression
J Clin Psychiatry 2007;68(suppl 8):17-25
© Copyright 2017 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Treatment-resistant depression (TRD) is a major public health problem in terms of its prevalence and in
terms of individual suffering and cost to society. Best estimates indicate 12-month prevalence rates of ~3%
for Stage 1 TRD (failure to respond to 1 adequate trial of an antidepressant) and ~2% for Stage 2 TRD (failure
to respond to 2 adequate trials). The current article provides a brief review of the definitions, prevalence,
and various treatment options for TRD, including switching, augmentation, and combination therapies and
use of nonpharmacologic treatments. Given the public health importance of TRD, the relative absence of
adequately powered, double-blind trials is striking.